Relapsed neuroblastoma is common, frequently lethal and poorly studied and poses a major treatment challenge. Two new studies shed light on the genomic landscape of recurrent neuroblastoma and demonstrate profound differences between the disease at diagnosis and relapse.
References
Pugh, T.J. et al. Nat. Genet. 45, 279–284 (2013).
Mossé, Y.P. et al. Lancet Oncol. 14, 472–480 (2013).
Eleveld, T.F. et al. Nat. Genet. 47, 864–871 (2015).
Schramm, A. et al. Nat. Genet. 47, 872–877 (2015).
Gerlinger, M. et al. Nat. Genet. 46, 225–233 (2014).
Aparicio, S. & Caldas, C. N. Engl. J. Med. 368, 842–851 (2013).
Sinha, G. J. Natl. Cancer Inst. 100, 84–85 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ramaswamy, V., Taylor, M. Pediatric cancer genomics, a play rather than a portrait. Nat Genet 47, 851–852 (2015). https://doi.org/10.1038/ng.3366
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.3366
- Springer Nature America, Inc.
This article is cited by
-
Precision medicine in pediatric oncology
Molecular and Cellular Pediatrics (2018)
-
Neuroblastoma treatment in the post-genomic era
Journal of Biomedical Science (2017)